Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 11/20 | 0.47 |
| ▸ | DRD2 | P14416 | 11/20 | 0.47 |
| ▸ | HTR2A | P28223 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13630548 | 1.00 | DRD3 (0.47) | DRD3DRD2HTR2AKMT2AHTR1A | |
| SCHEMBL13630044 | 0.95 | DRD3 (0.49) | DRD3DRD2HTR2AKMT2ACXCR3 | |
| SCHEMBL4489958 | 0.95 | DRD3 (0.49) | DRD3DRD2HTR2AKMT2ACXCR3 | |
| SCHEMBL4490607 | 0.90 | DRD3 (0.44) | DRD3DRD2HTR2AHTR1AHTR7 | |
| SCHEMBL13630549 | 0.90 | DRD3 (0.44) | DRD3DRD2HTR2AHTR1AHTR7 | |
| SCHEMBL4490569 | 0.89 | DRD2 (0.49) | DRD3DRD2HTR2AKMT2A | |
| SCHEMBL13630435 | 0.89 | DRD2 (0.49) | DRD3DRD2HTR2AKMT2A | |
| SCHEMBL4491759 | 0.88 | DRD3 (0.49) | DRD3DRD2HTR2AHTR7 | |
| SCHEMBL13629934 | 0.88 | DRD3 (0.49) | DRD3DRD2HTR2AHTR7 | |
| SCHEMBL13630258 | 0.87 | DRD2 (0.50) | DRD3DRD2HTR2AKMT2AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | claimed |
| EP-2038268-B1 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2015-11-04 | — | — | EP | disclosed |
| US-8802678-B2 | Carbonylated (aza) cyclohexanes as dopamine D3 receptor ligands | BIOPROJET (FR) | 2014-08-12 | — | — | US | disclosed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | DRD3, TACR2, TACR1 | DRD3 1/4885DRD2 4/4885HTR2A 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.